Skip to content
Inspirata and DeePathology Announce New Technical Partnership and Solution Integration
Inspirata and DeePathology Announce New Technical Partnership and Solution Integration

New technical partnership sees DeePathology’s AI-based Helicobacter Pylori Decision Support System integrated into Inspirata’s digital pathology workflow solution, Dynamyx™.


London, UK, Dec. 06, 2019 (GLOBE NEWSWIRE) — Cancer informatics and digital pathology provider Inspirata announced today a new technical partnership with Artificial Intelligence (AI) provider DeePathology affording joint customers with the ability to utilise DeePathology’s proprietary Helicobacter Pylori (H.Pylori) Decision Support System, directly from within Inspirata Dynamyx™, to improve reporting accuracy and safely accelerate the H. Pylori diagnostic process.

H. Pylori (HP) is a type of bacteria that lives within the digestive tract of approximately two-thirds of the global population.  While infection typically causes the carrier little or no issue, for a minority of individuals the presence of H. Pylori can lead to health complications such as stomach ulcers, and in certain circumstances, cancer.   Given the endemic nature of the bacteria, testing for H. Pylori in H&E and Giemsa-stained gastric biopsies is a routinely performed exercise.  However, present analogue testing methods require an intervention by a pathologist, are time-consuming and can often see relevant bacteria missed.  Moreover, inter and intra observer agreement when it comes to the detection of H. Pylori by expert pathologists is relatively low. To address this challenge, DeePathology has spearheaded an effort to explore how AI-based image analysis techniques could be used as a vehicle for assisting the pathologist find and confirm the likely presence of H. Pylori in a case.  This effort has culminated in the successful release of DeePathology’s H. Pylori Decision Support System.

“Our relentless focus on empowering customers to utilise best-of-breed AI solutions as a means of reducing the length of time, level of effort and instances of error in executing a case made the question of whether Inspirata should partner with DeePathology a very easy one to answer,” detailed Mark Lloyd Inspirata EVP and Founder.  “The ground-breaking work of DeePathology in H. Pylori detection really speaks for itself. Similarly, the integration of the H. Pylori Decision Support System into Dynamyx™ represents another tangible example of how open platforms and provider collaboration make it so much easier for clinical laboratories to embrace innovation in their efforts to improve patient outcomes.”

The shared Inspirata and DeePathology integration works by the H. Pylori Decision Support System automatically reading, detecting and ranking images consistent with the presence of H. Pylori as they are ingested into Dynamyx™.  The likely presence of H. Pylori is then flagged for the pathologist’s attention via a report made immediately available within the standard suite of diagnostic aids at their disposal.

With the debate around whether to digitise or not now firmly put to rest, we are increasingly being asked by the clinical community to demonstrate ‘what’s next’ in terms of new methods for reducing case-turnaround times and improving patient care,” said Inspirata Europe General Manager Tim Wing. “Our exciting new partnership with DeePathology is just one fantastic example of what is already immediately available to those healthcare providers who elect to partner with Inspirata for digital pathology.”

The DeePathology H. Pylori Detection Support System is complemented by DeePathology STUDIO™, a purpose-built platform designed specifically to enable pathologists and the research community create their own state of the art AI-based image analysis solutions.

“Whether our customers should choose to work with our productised solutions, or use DeePathology STUDIO™ to build their own algorithms, we recognise the critical role open digital pathology solutions have in seeing our functionality successfully applied in a clinical context,” said Chen Sagiv, DeePathology Co-Founder and Co-CEO. “Inspirata represent tremendous friends to DeePathology as exemplified at a technical level by the ease of our integration, and at a leadership level as reflected in their proactivity to bring us on board as partners.”

Inspirata revealed their new partnership with DeePathology as part of the company’s attendance at Digital Pathology and AI Congress in London.  Inspirata will be showcasing Dynamyx™ through one-to-one demonstrations at stand 29 throughout the two-day event.

About Inspirata Europe

Inspirata Europe Limited helps patients fighting cancer—and the clinicians they trust—to make every moment matter. Our comprehensive cancer informatics solutions bring disparate data together throughout the entire cancer care journey to drive informed decisions that improve survivorship.

Inspirata has assembled the most advanced and proven technologies to address the complex challenges of delivering cancer care and conducting ground-breaking research. We combine leading digital pathology solutions with automated cancer registry solutions, comprehensive cancer informatics and advanced patient engagement tools to bring users the broadest oncology informatics platform available globally. For more information, please visit or contact

About DeePathology

DeePathology offers the DeePathology Studio™ – a revolutionary Do It Yourself platform that enables pathologists and researchers to develop AI-based solutions through the provision of cell and objects detection and classification and region segmentation functionality. DeePathology also offers customised AI solutions for digital pathology specifically, leveraging our expertise and experience of deep-learning and pathology.  For more information, please visit or contact


Graeme Collins
Inspirata Europe Limited
+44 7854 664168

Inspirata Joins Advarra’s New API Partner Program as an Inaugural Member

Inspirata Joins Advarra’s New API...

As new partners, Inspirata and Advarra will collaborate on ensuring integrations between Inspirata's Trial Navigator and Advarra's OnCore.
Inspirata Receives Industry’s First FDA Clearance for Scanner Agnostic Digital Pathology Software

Inspirata Receives Industry’s First FDA...

Inspirata is proud to announce that Dynamyx now holds the industry's first FDA clearance for digital pathology software with multiple…
NHS Cancer Alliance Implements Inspirata AI to Improve Clinical Trial Access for South West Patients

NHS Cancer Alliance Implements Inspirata...

NHS Cancer Alliance Implements Inspirata AI to Improve Access to Clinical Trials Across Somerset, Wiltshire, Avon and Gloucestershire.